Subject category:
Production and Operations Management
Published by:
Harvard Business Publishing
Version: 13 May 2002
Length: 20 pages
Data source: Field research
Abstract
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme''s business model under new pressures.; Illustrates novel approach to targeting drug markets and creative ways to use external technology.
About
Abstract
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme''s business model under new pressures.; Illustrates novel approach to targeting drug markets and creative ways to use external technology.